Slide 1: For personal use only
For personal use only PRESENTED BY: Jeremy Steele DATE PRESENTED: 30 May 2023 VERSION: 1.0 Private & Confidential. Copyright © Control Bionics 2023
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 3: Our flagship product
For personal use only Our flagship product
Slide 4: Executive Summary
EXECUTIVE SUMMARY For personal use only ∙ Control Bionics (ASX:CBL) is a pioneer in the field of neuroelectric control by using smart algorithms to detect, synthesise and convert electromyography (EMG) signals into code which can interact with and control a broad range of electronic devices ∙ Follow
Slide 5: Leadership Team
LEADERSHIP TEAM • Over 25 years of global corporate experience across a wide range of industries including healthcare and software For personal use only • Previously CEO of CardioScan, driving international expansion (from 1 to 10 countries) BOARD Jeremy Steele • Led greenfield expansion as well as
Slide 6: Who is Control Bionics?
WHO IS CONTROL BIONICS? For personal use only ∙ Control Bionics is a pioneer in the field of neuroelectric control by using smart algorithms to detect, synthesise and convert electromyography (EMG) signals into code which can interact with and control a broad range of electronic devices ∙ EMG measur
Slide 7: How We Work
HOW WE WORK For personal use only Opportunity origination Product Selection Trial/Rental Purchase/funding Payment terms USA - Our sales people have developed a - Our sales person works - Most US funds require - We work with the local - Varies by payor network of referral sources to with the care tea
Slide 8: Our Performance in FY23
OUR PERFORMANCE IN FY23 For personal use only ∙ We expect to deliver strong revenue growth in FY23 over FY22 with revenue forecast to grow more than 15% with revenue expected to top $5m ∙ Both core markets have grown in FY23, with Australia forecast to deliver in excess of 25% growth and the US over
Slide 9: Our Strategy Priorities for FY24
OUR STRATERGY PRIORITIES FOR FY24 For personal use only We expect organic revenue growth in excess of 20% for FY24, with both core markets forecast to deliver strong year on year growth Our core pillars for success in FY24 are: ∙ Drive growth in the US to reach monthly breakeven ∙ Accelerate growth
Slide 10: USA
CORE PILLARS IN FY24 For personal use only USA • We are forecasting growth in the US in excess of 15% for FY24. This growth will be delivered through more effective sales strategies, strengthening of our 3rd party distributor sales and improved sales mix • Software and hardware releases planned duri
Slide 11: Australia
CORE PILLARS IN FY24 For personal use only AUSTRALIA • We are forecasting strong organic growth in the Australian business in excess of 30% for FY24 • We have already added to resources to our Australian sales team and have seen the benefits almost immediately of improved monthly sales • We now have
Slide 12: Japan / International
CORE PILLARS IN FY24 For personal use only JAPAN / INTERNATIONAL • Initial learnings from the Japanese market are that selling the Neuronode standalone into the Japanese market is the best strategy • To ensure success we need to further invest in our software to facilitate take up of this in the AAC
Slide 13: Software
CORE PILLARS IN FY24 For personal use only SOFTWARE • We are confident there is a significant opportunity to lift sales of the Neuronode and Neuronode-led products through software enhancements to our controller software • Through investing in our Neuronode software capabilities, we will be able to
Slide 14: DROVE
CORE PILLARS IN FY24 For personal use only DROVE • DROVE was successfully launched in Q4 FY23 and we are currently completing final testing before we launch commercially • We expect the NDIS to fully fund the system for appropriate applicants • We have 10 units in production that will be provided to
Slide 15: 3rd Party Products
CORE PILLARS IN FY24 For personal use only 3RD PARTY PRODUCTS • We are advancing work on the balance of the 3rd party products we use in our Trilogy solution to improve margin, product attractiveness and scalability • Our inhouse industrial designer and our investment in our software capabilities al
Slide 16: Our People
CORE PILLARS IN FY24 For personal use only OUR PEOPLE • Our people are critical to our success • We need to ensure our people management matures and staff understand our expectations of them around performance and supported to deliver • Building career plans, ensuring appropriate training and puttin
Slide 17: How Good Is the Opportunity for Control Bionics?
HOW GOOD IS THE OPPORTUNITY FOR CONTROL BIONICS? For personal use only ∙ Control Bionics has patented EMG technology that is unique and has already demonstrated commercial viability ∙ In the first market in which it has been commercialised (AAC) we have shown that it successfully improves outcomes f
Slide 18: Thank You
THANK YOU For personal use only JEREMY STEELE jsteele@controlbionics.com +65 9011 3975 www.controlbionics.com